| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3696b0a5c800add4fbf4460737ed94a1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-54 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57446
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2012-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecc341a1d5d284cbf008ab22850412f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edf2d7a0a709fa02fea6b74bbd974191 |
| publicationDate |
2017-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2639650-T3 |
| titleOfInvention |
Methods to predict and improve the survival of patients with gastric cancer |
| abstract |
An in vitro method to predict the survival of a subject who has stage I gastric cancer after tumor surgery, the method comprising: (a) determining the presence of activation or the level of activation of at least two analytes comprising cMET and HER1 in a cancer cell obtained from the subject, where cMET and HER1 are co-activated in the cancer cell; and (b) predicting the survival of the subject based on the presence of activation or the activation level of said at least two analytes determined in step (a), where the subject is predicted to have worse survival than gastric cancer subjects. stage I with cMET activation in the absence of HER1 activation. |
| priorityDate |
2011-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |